(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Slides:

Advertisements

Similar presentations

Glenn N. Levine et al. JACC 2016;68:

Advertisements

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Change in symptoms in operated and unoperated patients 1 year following evaluation of surgical AVR. Pie charts display change from baseline to follow-up.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Masashi Maeda et al. Heart Asia 2013;5:7-14

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Gordon R. Reeves et al. JCHF 2017;j.jchf

Bar chart of systolic function in healthy individuals, HCM LVH− patients and HCM LVH+ patients. GLS was significantly worse in the HCM LVH+ patients compared.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:

Comparison of CMR and echocardiography in aortic regurgitation.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Changes in median exhaled CO levels from baseline to 12 weeks in quitters (n=183) and continuous smokers (n=94). Changes in median exhaled CO levels from.

Distribution of relative percentage change ((post-AVR−pre-AVR)/pre-AVR) in the patients’ absolute pVO2 values between pre-AVR and post-AVR after 9 months.

Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Venn diagram of patients with paired pre-cardiac resynchronisation therapy (CRT) and post-CRT echocardiograms. Venn diagram of patients with paired pre-cardiac.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Flow-mediated and nitrate-mediated dilation in following radial artery catheterisation. Flow-mediated and nitrate-mediated dilation in following radial.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Cost of healthcare and sick leave before and after heart valve surgery (€). Cost of healthcare and sick leave before and after heart valve surgery (€).

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

(A) Absolute and B) change from baseline in 6 min walk distance over time for patients on bosentan monotherapy by Down syndrome status. (A) Absolute and.

The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.

Simpson's biplane ejection fraction (A), and two-dimensional speckle-tracking global longitudinal strain (B) in patients receiving clozapine treatment,

Changes in 6 min walk distance (6MWD) for combined pulmonary fibrosis and emphysema (CPFE) (n=15), and chronic obstructive pulmonary disease (COPD) (n=37).

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

OPN is elevated in patients with symptomatic AS

(A): Five-year mortality in unoperated patients with severe MR with E/E′≥15 was significantly higher compared with patients with E/E′

Impact of preoperative MG below 40 mm Hg and presence of postoperative PM on frequency of a decline in absolute pVO2 of more than 10% between pre-AVR and.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

The fractional flow reserve (FFR) values according to increasing risks of the Multifunction CardioGram (MCG) scores. The fractional flow reserve (FFR)

Mean pulmonary arterial systolic pressure (PASP) with 95% CI error bars and individual data points at rest breathing room air (baseline), during 20 min.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Impact of preoperative AVAI<0

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

Countries and areas of the Western Pacific region included within the scope of this study. Taiwan does not have WHO Member State status but is within this.

Vitamin D3 increased ASL antimicrobial activity in non-smokers.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Profile of diastolic function parameters at rest, immediately post-exercise and into recovery. Profile of diastolic function parameters at rest, immediately.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

One-year costs by evaluation strategy.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Distribution of patient baseline characteristics among included studies. Distribution of patient baseline characteristics among included studies. Each.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Mean with 95% CI error bars and individual data points of right ventricular function parameters at rest breathing room air (baseline), during 20 min breathing.

Box plots showing the distribution of baseline brachial artery flow-mediated dilation (FMD) and nitroglycerine-mediated dilation (NMD). Box plots showing.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. For the patients who had data post 24 months the mean±SD treatment duration from commencement of therapy to the latest time point was 4.1±1.1 (median 3.9 years, range 2.5–6.9 years) for all patients (n=38), 4.1±1.1 (median 3.8 years, range 2.5–6.1 years) for patients without Down syndrome (n=29) and 4.2±1.2 (median 4.0 years, range 2.6–6.9 years) for patients with Down syndrome (n=9). p Values tested whether change in 6MWD from baseline at each time point was significantly different from no change; *p<0.05, ***p<0.0001. 6MWD, 6 min walk distance; DS, Down syndrome. Oliver Monfredi et al. Open Heart 2016;3:e000399 ©2016 by British Cardiovascular Society